The mRNA decay factor tristetraprolin (TTP) induces senescence in human
                        papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin









































Cervical cancer is the second most common cancer 
among women worldwide [1]. A necessary factor in the 
development of nearly all cases of cervical cancer is 
infection with the high-risk human papillomavirus 
(HPV) types 16 and 18 [2]. These subtypes of HPV 
promote cellular transformation through expression of 
the early viral genes E6 and E7. The HPV E7 protein 
neutralizes the retinoblastoma (Rb) tumor suppressor 
pathway by sequestering Rb from E2F and promoting 
its destabilization [3, 4], while the E6 protein promotes 
degradation of the p53 tumor suppressor and activates 
transcription of the human telomerase reverse 









































tions of E6 occur through its interaction with a number 
of cellular regulatory proteins and one of the best 
characterized E6-binding partners is the E6-associated 
protein (E6-AP) [7, 8]. E6-AP belongs to a class of 
HECT ubiquitin-protein ligases [9] and its interaction 
with E6 facilitates cell transformation through enhanced 
p53 protein degradation and activation of hTERT gene 
expression [10]. Deregulation of these critical factors 
through the combined action of E6 and E7 oncoproteins 
allows for continued cell proliferation and genomic 
instability ultimately leading to HPV-mediated cellular 
transformation. 
Messenger RNA turnover is a tightly regulated process 
that plays a central role in controlling mammalian gene 
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and tumorigenesis where loss of post-transcriptional gene 
regulation accounts for the aberrant overexpression of a 
variety of genes encoding growth factors, inflammatory 
cytokines and proto-oncogenes [11, 12]. A majority of 
cancer-associated immediate-early response genes that 
control growth and inflammation display conserved cis-
acting adenylate- and uridylate (AU)-rich elements 
(ARE) in the mRNA 3' untranslated region (3’UTR). A 
primary function of the ARE is to target mRNAs for 
rapid decay through interaction with trans-acting RNA-
binding proteins that have high affinity for AREs. 
Among the best characterized ARE-binding proteins 
involved in promoting ARE-mediated mRNA decay is 
tristetraprolin (TTP, ZFP36, TIS11). TTP is a member of 
a small family of tandem Cys3His zinc finger proteins 
originally identified as an inducible immediate-early 
response gene [13]. Initially thought to be a transcription 
factor, various studies have established the role of TTP as 
an mRNA decay protein that binds to AREs in the 
mRNA of various inflammatory mediators (e.g. TNF-α, 
GM-CSF, COX-2) [14-16]. The binding of TTP to ARE-
mRNAs targets them for rapid degradation through 
association with various decay enzymes [14, 17-21]. The 
physiological role of TTP is significant as TTP deficient 
mice develop a number of inflammatory syndromes. 
These abnormalities have been shown to be due to exces-
sive levels of pro-inflammatory factors resulting from 
defects in ARE-mediated decay in these mice [22, 23]. 
 
In this study, we examined the role of TTP in HPV-
mediated cervical carcinogenesis. Expression of TTP in 
HPV18-positive HeLa cells dramatically inhibited cell 
growth by inducing cellular senescence through a 
mechanism involving p53 protein stabilization and 
inhibition of telomerase expression. It was found that 
TTP induced cellular senescence through rapid decay of 
E6-AP ubiquitin ligase mRNA that was mediated 
through the ARE-containing 3'UTR of E6-AP. 
Furthermore, we demonstrate that TTP expression is 
lost in cervical cancer compared to normal tissue, 
implying a tumor suppressor function for TTP in 
cervical tissue. These novel findings not only add 
another attribute to the already established anti-
inflammatory role of this ARE-binding protein but also 
bring new insights into the mechanism of HPV-




TTP-mediated induction of senescence in HeLa cells 
 
Based on its ability to control expression of ARE-
containing mRNAs associated with various aspects of 










































































www.impactaging.com                   804                                  AGING, September 2009, Vol.1 No.9in a tumor suppressor capacity. To test this in HPV-
transformed cervical carcinoma cells, a tetracycline 
(Tet)-regulated TTP expression system in HeLa cells 
was developed. HeLa Tet-Off cells were stably 
transfected with a Flag epitope-tagged TTP cDNA in a 


















































the absence of doxycycline (Dox) allow for the 
expression of TTP (Figure 1A). Consistent with other 
findings [24, 25], endogenous TTP expression was 
undetectable in HeLa cells and in HeLa Tet-Off parental 
cells grown in the presence or absence of Dox (Figure 





























































www.impactaging.com                    805                                 AGING, September 2009, Vol.1 No.9To determine the consequence of TTP expression, we 
evaluated the ability of TTP to attenuate HeLa cell 
growth and proliferation. As shown in Figure 1B, HeLa 
Tet-Off/TTP-Flag cells grown in the absence of Dox 
showed a marked reduction in proliferation and this 
effect was dependent on TTP; re-addition of Dox to turn-
off TTP expression allowed for increased cell growth. 
Consistent with this, a decreased rate of DNA synthesis 
was observed in HeLa cells expressing TTP and similar 
results were obtained from 3 other independent HeLa 
Tet-Off/TTP-Flag clones (data not shown). Interestingly, 
HeLa cells grown in the presence of TTP for 48 hr 
exhibited a flattened morphology resembling cells that 
had undergone replicative senescence (Figure 1C, [26]). 
Upon longer exposure to TTP (12 days), these cells 
contained elevated levels of senescence-associated β-
galactosidase (SA β-gal) [27] further indicating the 
ability of TTP to attenuate HeLa cell growth through a 
mechanism involving cellular senescence.  
 
TTP promotes p53 expression through protein 
stabilization  
 
HPV oncogenicity is mediated through the interaction 
between HPV E6 protein and the tumor suppressor p53 
with E6 promoting accelerated ubiquitin-mediated 
degradation of p53 [7, 10]. Based on this, we sought to 
determine if the growth inhibitory effect exerted by TTP 
was being modulated through p53 activation. As shown 
in Figure 2A, induction of TTP in HeLa Tet-Off/TTP-
Flag cells resulted in increased expression of p53 
protein. Similarly, infection of HeLa cells with an 
adenovirus expressing TTP resulted in enhanced p53 
protein expression as compared to cells infected with 
control adenovirus expressing GFP (Figure 2A). The 
ability of TTP to promote p53 expression appeared to 
be through protein stabilization since p53 mRNA levels 
were not respectively increased with TTP induction 
(Figure 2B). To specifically test this, HeLa Tet-
Off/TTP-Flag cells were grown in presence or absence 
of TTP for 48 hr and then treated with cycloheximide 
(CHX) to inhibit protein synthesis. In the presence of 
TTP, the half-life of p53 protein was increased 3-fold 
(Figure 2C), indicating the ability of TTP to inhibit p53 
protein turnover. 
 
Activation of p53 promotes its accumulation in the 
nucleus and transcription of p53-responsive promoters 
[28, 29]. To determine if nuclear localization of p53 is 
occurring in cells expressing TTP, HeLa Tet-Off/TTP-
Flag cells were examined for p53 localization by 
immunofluorescence. In cells grown in the presence of 
TTP, p53 was detected in both the nucleus and 
cytoplasm with a high level of p53 localized to the 
nucleus (Figure 3A). In parallel experiments, a reporter 
construct containing a p53-dependent promoter was 
transfected into HeLa Tet-Off/TTP-Flag cells and its 
activity was examined in the presence and absence of 
TTP (Figure 3B). The magnitude of promoter activity 
was significantly increased in the presence of TTP, 
consistent with observed p53 protein stabilization and 





















































(B)  Expression  of  TTP  induces  p53  transcriptional  activity.
Luciferase  reporter  constructs  containing  either  a  p53‐
dependent promoter (pp53‐Luciferase) or control vector (pTA‐
Luciferase) were transfected into HeLa Tet‐Off/TTP‐Flag cells and





















































TTP expression downregulates telomerase activity 
 
Elevated telomerase activity is associated with 
approximately 85% of human cancers [30]. In cervical 
cancers, the HPV E6 protein induces telomerase activity 
by promoting expression of the catalytic subunit of 
telomerase, hTERT [31]. To determine if TTP 
expression impacted hTERT levels, HeLa Tet-Off/TTP-
Flag cells were grown in the presence and absence of 
Dox for 48 hr and hTERT mRNA and protein was 
evaluated. As shown in Figure 4A, steady state levels of 
both hTERT mRNA and protein were dramatically 
reduced in presence of TTP. Consistent with this 
inhibition, a decrease in telomerase activity was also 
detected (Figure 4B). In cells expressing TTP, a 
decrease in the characteristic laddering using a 
telomeric repeat amplification protocol (TRAP) assay 
was observed indicating that TTP inhibits telomerase 
activity through inhibition of hTERT expression. 
 
TTP promotes downregulation of E6-AP ubiquitin 
ligase 
 
In high-risk HPV-transformed cells, the cellular 
ubiquitin ligase E6-associated protein (E6-AP) plays a 
central role in mediating the oncogenic functions of E6. 
E6-AP couples with E6 to target p53 for proteasomal 
degradation [32]. This complex also degrades the 91 
kDa isoform of NFX1 (NFX1-91) which is a repressor 
for the hTERT promoter, allowing for constitutive 
hTERT expression in HPV-positive cells [5, 33]. Based 
on this, we examined if TTP could inhibit E6-AP 
expression in order to establish a molecular explanation 
underlying TTP's ability to promote senescence. As 
shown in Figure 5AB, HeLa Tet-Off/TTP-Flag cells 
grown in the presence of TTP showed downregulation 
of both E6-AP mRNA and protein. Similarly, HeLa 
cells infected with adenovirus expressing TTP also 
showed inhibition of E6-AP expression (Figure 5B, 
right panel). As a control, the RNA levels of HPV18-E6 
and -E7 were assayed (Figure 5A, right panel) and no 
change was observed in the presence of TTP, indicating 
that the viral transcript is not a target of TTP. 
Furthermore, re-addition of Dox to TTP-expressing 
HeLa Tet-Off/TTP-Flag cells to suppress TTP 
expression allowed for rapid recovery of E6-AP 





analysis  (top  panel)  and  western  blot  using  nuclear  lysates
(bottom  panel).  GAPDH  and  nucleoporin  were  detected  as
loading  controls,  respectively.  (B)  TRAP  assay  showing
inhibition  of  telomerase  activity  in  TTP‐expressing  cells.  0.5
and 1 µg of lysate from cells grown in the absence or presence
of  TTP  was  used  for  TRAP  assay  as  described  in  Methods.
Control reaction lacks Taq polymerase. 
  
TTP-mediated stabilization of p53 via  E6-AP 
downregulation occurs in high-risk HPV positive cell 
lines 
 
HPV16 and HPV18 high-risk types are most frequently 
associated with cervical carcinomas [2]. To determine if 
these results extended to HPV16-positive cervical 
cancer cells, SiHa (HPV16+) and CaSki (HPV16+) cells 
were infected with adenovirus expressing TTP or 
control GFP. As shown in Figure 5D, endogenous TTP 
was not detected in either SiHa and CaSki cells, 
whereas adenoviral delivery of TTP led to E6-AP 
downregulation and elevated levels of p53 protein in 
both HPV16+ cell lines to a similar extent to that 
observed in HPV18+ HeLa cells. 
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decay 
 
Rapid mRNA decay mediated by TTP occurs through 
cis-acting AU-rich RNA elements (AREs) present in the 
3'UTR of target transcripts [22, 34]. Within the 3'UTR 
of E6-AP, we detected multiple overlapping copies of 
AUUUA motif characteristic of Class II AREs (Figure 
6A, [35]) suggesting E6-AP mRNA to be a target of 
ARE-mediated decay. To evaluate this, the half-life of 
E6-AP mRNA was assessed by qPCR after 
actinomycin-D (ActD) was added to HeLa Tet-
Off/TTP-Flag cells to halt transcription. In cells 
expressing TTP rapid E6-AP mRNA decay was 
observed yielding a half-life of approximately 90 min 
(Figure 6B). In contrast, E6-AP mRNA was stable in 







































To determine if this shortening of half-life was a result 
of TTP binding to E6-AP mRNA, cytoplasmic extracts 
from HeLa Tet-Off/TTP-Flag cells grown in the 
presence and absence of TTP were subjected to 
immunoprecipitation using anti-Flag antibody or control 
IgG. Co-immunoprecipitated mRNA was reverse 
transcribed and PCR amplified using primers specific 
for E6-AP and GAPDH. Shown in Figure 6C, E6-AP 
was amplified from TTP expressing cells while no 
products were detected in control reactions. Samples 
were also analyzed by qPCR and the Ct values were 
used to detect the presence of a specific mRNA (Figure 
6D). Ct value for E6-AP was 38 in the mRNA pool from 
TTP expressing cells and undetectable in cells absent of 
TTP. Ct values were undetectable for GAPDH mRNA 










































E6‐AP  mRNA.  The  grey  bar  corresponds  to  E6‐AP 














lysed  and  immunoprecipitation  was  performed  on 
equal amounts of cytoplasmic lysates using control 
IgG  or  anti‐Flag  mAb.  RNA  purified  from  immuno‐
precipitates was subjected to RT‐PCR (C) or qPCR (D) 
to  detect  E6‐AP  and  GAPDH  mRNA.  The  ethidium
bromide‐stained agarose gel depicting the 292bp E6‐
AP  PCR  product  is  shown  in  reverse  image.  The 
relative  amounts  of  immuno‐precipitated  E6‐AP 





















































To determine if the ARE-containing 3'UTR of E6-AP 
mediated post-transcriptional regulation through TTP,   
HeLa Tet-Off/TTP-Flag cells were transiently 
transfected with a cDNA expression construct 
containing the 2.5 kb coding region of E6-AP (E6-
APΔ3’UTR), and protein expression was assayed in the 
presence or absence of TTP. We found no TTP-
dependent changes in the amount of E6-AP protein 
expressed when the 3'UTR was absent (Figure 7A) and 
expression of E6-APΔ3’UTR completely abrogated 
TTP-mediated stabilization of p53 and subsequent p53-
dependent transcriptional activity (data not shown). The 
ability of the E6-AP 3'UTR to confer TTP-dependent 
mRNA instability to a reporter was tested by 
transfecting HeLa cells with a luciferase reporter 
containing the 1.6 kb E6-AP 3’UTR (Luc+E6-AP 
3'UTR) along with a TTP expression construct. As seen 
in Figure 7B, the E6-AP 3’UTR significantly inhibited 
luciferase expression in presence of TTP, whereas 
control transfections using luciferase without a 3'UTR 
was inhibited by TTP to a much lesser extent. Taken 
together, these results indicate E6-AP mRNA to be a 
novel target of TTP-mediated mRNA decay through its 
ARE-containing 3'UTR. 
 
TTP expression is lost in cervical cancer  
 
Based on its ability to target E6-AP mRNA for rapid 
decay, these results suggested that the presence of TTP 
would be inhibitory to HPV-mediated tumorigenesis 
and loss of TTP would be observed in cervical cancer. 
To test this, TTP expression was evaluated by 
immunohistochemistry using human tissue arrays 
containing cervical tissue sections from both normal 
and squamous cell carcinoma (Figure 8A). In normal 
cervical tissue (left panel) strong cytoplasmic staining 
of TTP was observed in the cells of squamous 
epithelium, whereas TTP immunoreactivity was 
negative or substantially decreased in tissue sections 
from squamous cell carcinomas (right panel). Tissue 
sections were assigned immunoreactivity scores (IRS) 
and grouped as low IRS of 0 to 6 or high IRS of 7 to 12 
(Figure 8B). In normal tissue, TTP immuno-reactivity 
was high (median IRS of 10) in 8 of 10 (80%) samples, 
while expression was significantly lower (median IRS 
of 2) in 40 of 56 squamous cell carcinoma samples 
(71%,  P < 0.001). These results are consistent with 
recent findings demonstrating elevated TTP mRNA 
levels to be present in normal cervix tissue [36] and 
suggest that loss of TTP expression in cervical cancer 
cells allows for aberrant mRNA stabilization and 
enhanced expression of E6-AP. 
Figure  7.  E6‐AP  3'  UTR  is  necessary  for  TTP‐mediated
decay. (A) HeLa Tet‐Off/TTP‐Flag cells were transfected with an
expression  vector  containing  the  coding  region  of  E6‐AP  (E6‐
APΔ3’UTR). Cells were grown in the absence or presence of TTP
for 48 hr and lysates were analyzed for E6‐AP and TTP protein
expression  by  western  blot.  Actin  was  detected  as  a  loading
control.  (B)  HeLa  cells  were  transfected  with  a  luciferase‐
reporter construct containing the 1.6 kb E6‐AP 3’UTR (Luc+E6‐AP
3'UTR) or the control luciferase vector (no 3’UTR) along with a
TTP  expression  construct  (pcDNA3‐TTP‐Flag)  or  empty  vector.
Relative luciferase reporter activity in the absence (black bars) or
presence  (grey  bars)  of  TTP  is  shown.  Relative  activity  was
assessed  as  luciferase  activity  normalized  to  its  respective
protein concentration for each transfection in the absence or





Normal cellular growth is associated with rapid decay 
of ARE-containing mRNAs and targeted mRNA decay 
is an essential way of controlling their pathogenic 
overexpression. However, a number of observations 
have implicated loss of ARE-mediated post-
transcriptional regulation in the neoplastic transforma-
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instability of tumor cells, it might be expected that 
mutations in AREs are a frequent event. However, few 
naturally occurring mutations in AREs have been 
described [37]. This implies that loss of ARE function 
in tumor cells is primarily due to altered recognition of 
AU-rich sequences by trans-acting RNA-binding 
regulatory factors. 
 
Through their ability to selectively bind and control 
expression of many cancer-associated transcripts [12], 
ARE RNA-binding proteins are being acknowledged as 
central regulators influencing various aspects of 
tumorigenesis. Along with its recognized ability to target 
rapid decay of an array of inflammatory mediators, the 
ARE-binding protein TTP has been shown to inhibit 
expression of a wide range of cancer-associated factors 
[25, 38-44]. Consistent with this, expression of TTP was 
shown to inhibit cell growth and tumorigenesis in a mast 
cell tumor model [45] and attenuate colon cancer cell 
growth and proliferation [44]. These aspects, taken 
together with the results presented here, indicate that TTP 
can serve in a tumor suppressor capacity by controlling 
ARE-containing gene expression.    
 
Through its ability to promote rapid mRNA decay, the 
tumor suppressor ability of TTP should reflect the ARE-
containing mRNAs needed for enhanced tumor cell 
growth and survival. Previous findings have indicated 
that TTP overexpression can promote apoptosis in 
various cells lines [46]. The results presented here using 
HPV-positive cervical cancer cells demonstrate the 
ability of TTP to inhibit cell growth. However, in this 
TTP-inducible system evidence of apoptosis was not 
observed as indication of caspase-3 activation, nuclear 
condensation, and DNA fragmentation was not apparent 
in HeLa cells expressing TTP over a 7 day time course 
(data not shown) indicating that TTP-mediated growth 
inhibition was occurring through an alternate 
mechanism in HeLa cells. In our findings, HeLa cells 
expressing TTP exhibited a flattened morphology and 
elevated levels of β-galactosidase activity indicating 
they have undergone replicative senescence. These 
findings are in agreement with recent results 
demonstrating TTP-mediated growth inhibition using a 
similar TTP-inducible HeLa cell model [25]. These 
differences in phenotypic outcome resulting from TTP 
expression in cells may reflect a specific variation in the 
ARE-containing mRNAs targeted for TTP-mediated 
decay in the differing cell types. 
 
In HeLa cells, repression of viral E6 and E7 oncogene 
expression can trigger endogenous senescence pathways 
[47-50]. Although our results could be explained 










































cancer.  (A)  Immunohistochemical  detection  of  TTP  expression  in 
normal cervix and squamous cell carcinoma. Representative tissue
sections were examined for TTP expression and counterstained with
hematoxylin.  Original  magnification  x  200.  (B)  Immunoreactivity 
scores (IRS) for TTP expression in tissue sections of normal cervix 
and  squamous  cell  carcinoma.  The  line  indicates  the  division  of
samples with high IRS from 7‐12 and low IRS from 0‐6. 
 
we did not observe any TTP-dependent changes in 
E6/E7 transcript level (Figure 5A). Interestingly, an 
AU-rich region has been identified within the 3'UTR of 
HPV16 E6/E7 RNA that can mediate rapid decay [51]. 
The results presented here (Figure 8) and that of others 
[36] demonstrate TTP to be abundantly expressed in 
normal uterine cervix. Based on these observations, it is 
plausible that that TTP may play a protective role in the 
early stages of HPV infection by targeting E6/E7 RNA 
for rapid degradation. However, this viral ARE is lost in 
cells containing integrated HPV16 genomes through the 
process of viral DNA linearization and host genome 
integration [51] and the consequences of this would 
make E6/E7 RNA resistant to TTP-mediated decay. 
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disruption of the viral E2 transcriptional repressor [52], 
would potentiate persistent E6/E7 oncogene expression 































Actively growing HeLa cells maintain a dormant p53 
pathway and elevated telomerase activities [49]. The 
results presented here demonstrate the ability of TTP to 
promote p53 protein expression, which is consistent 
with senescent growth arrest that is often associated 
with an active p53 pathway [53]. In normal cells, p53 
levels are under negative regulation of Mdm2 ubiquitin 
ligase and p53 pathway activation primarily involves 
signal-dependent escape from degradation [54, 55]. 
Whereas in high-risk HPV-transformed cervical cancer 
cells, the viral oncoprotein E6 binds to p53 and with the 
help of the cellular ubiquitin ligase E6-AP, p53 is 
targeted for constitutive degradation through the 
ubiquitin proteasomal pathway [6, 32, 56].  
 
Replicative senescence in somatic cells is in part 
attributed to gradual loss of telomeres, while high 
telomerase activity is observed in a majority of cancer 
cells [30]. Another characteristic of cervical cancer cell 
transformation is reactivation of hTERT gene 
expression, which is the catalytic component of 
telomerase. Although the mechanism of E6-dependent 
activation of hTERT  is not entirely defined in HPV-
transformed cells, current observations indicate the 
involvement of E6-AP in targeting a regulator of 
hTERT expression [5, 33, 57]. Furthermore, p53 can 
serve as a negative regulator of hTERT expression [58], 
suggesting that E6/E6-AP-dependent degradation of 
p53 may also play a causal role in hTERT promoter 
activation.  
 
Central to the deregulation of these factors in cervical 
cancer is E6-AP and the results presented here are 
readily explained with E6-AP being a novel target of 
TTP-mediated post-transcriptional regulation (Figure 
9). Within the 3'UTR of E6-AP, the presence of AU-
rich elements provide a binding site for TTP and this 
functional interaction targets E6-AP mRNA for rapid 
ARE-mediated decay. These results are supported by 
the observations that the presence of E6-AP 3’UTR to a 
luciferase reporter renders it susceptible to TTP-
mediated downregulation and deletion of the 3'UTR 
from E6-AP makes it resistant to TTP-mediated mRNA 
decay (Figure 7). The functional consequences of TTP-
mediated suppression of E6-AP leads to p53 stabiliza-
tion, hTERT inhibition, and cellular senescence. These 
results are consistent with those using RNA interference 
to downregulate E6-AP expression indicating the 
central role E6-AP has in promoting HPV-associated 
cervical cancer [59].  
Figure  9.  TTP‐mediated  regulation  of  E6‐AP  in  cervical 
cancer cells. The binding of TTP to the ARE‐containing E6‐AP 
mRNA  targets  it  for  rapid  degradation.  Black  ovals  represent
putative 3' UTR AU‐rich elements (AREs). The subsequent loss of
E6‐AP expression allows for concurrent p53 protein stabilization
and  inhibition  of  hTERT  transcription  leading  to  cellular
senescence.  
 
Recent findings have demonstrated that loss of TTP 
expression is observed in a variety of tumor types [25, 
36, 44, 60]. Consistent with this, we also observe a 
similar loss of TTP in cervical cancer cells and tumors. 
This loss of TTP expression appears to be a critical 
factor in the progression of high-risk HPV-associated 
cervical cancer, since the presence of TTP in cervical 
tumor cells impedes their tumorigenic potential through 
rapid decay of E6-AP mRNA. Also observed with the 
loss of TTP expression is increased expression of the 
ARE-mRNA stabilization factor HuR in cervical 
cancers [61]. Through these combined defects of TTP 
loss-of-function and HuR gain-of-function, aberrant 
mRNA stabilization can occur leading to over-
expression of cancer-associated factors in cervical 
cancer similar to what is seen in colon cancer [44]. 
Moreover, the potential of TTP to promote senescence 
may be through its ability to antagonize HuR-mediated 
stabilization of proliferative ARE-mRNAs [44, 62] 
similar to observations showing that reduction in HuR 
levels in fibroblasts promoted a senescent phenotype 
[63]. 
 
The mechanisms underlying the loss of TTP expression 
in cervical cancer cells and tumors are largely 
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19q13.1 and does not appear to be a target of genomic 
loss or rearrangement in cervical cancer [64]. One 
explanation for the lack of TTP expression observed in 
tumor tissue may reside in epigenetic silencing of the 
TTP promoter. Within the proximal 3' region of the 
human TTP promoter lies a putative CpG island and the 
presence of hypermethylation of this region was 
observed in HeLa cells (unpublished observations). 
Based on this we hypothesize that epigenetic alterations 
occurring through changes in DNA methylation and 
altered chromatin structure promote TTP gene silencing 
in cervical tumors. This is consistent with observations 
demonstrating that various tumor suppressor genes have 
been silenced or display decreased expression resulting 
from abnormal promoter hypermethylation in HPV-
associated cervical carcinoma [65]. 
 
The results presented here provide a novel link between 
post-transcriptional gene regulation and HPV-associated 
cervical tumorigenesis. Based on these findings we 
conclude that TTP promotes cellular senescence in 
cervical cancer cells through rapid decay of E6-AP 
mRNA leading to p53 protein stabilization and 
inhibition of hTERT transcription. Moreover, absence of 
TTP expression in cervical cancer strongly implicates 
that loss of TTP expression is a critical step that occurs 
early in HPV-mediated carcinogenesis. These findings 
demonstrate the novel ability of TTP to serve in a tumor 
suppressor capacity by regulating ARE-mRNA gene 
expression and identify how defects in post-





Cell culture, DNA transfection, and adenoviral 
infection.  Human cervical cancer cell lines HeLa 
(HPV18+), SiHa (HPV16+) and CaSki (HPV16+) cells 
were obtained from ATCC; HeLa Tet-Off cells were 
purchased from BD Clontech. Cells were maintained in 
DMEM supplemented with 10% fetal bovine serum 
(FBS; Hyclone); HeLa Tet-Off cell media was 
supplemented with 100 µg/ml G418 (Cellgro). The Tet-
responsive pTRE2hyg/TTP-Flag vector was created by 
cloning an N-terminal Flag epitope-tagged TTP cDNA 
from pcDNA3-Flag-TTP (kindly provided by N. 
Kedersha, Brigham and Women's Hospital, Boston, 
MA) into pTRE2hyg (Clontech). HeLa Tet-Off cells 
were stably transfected with pTRE2hyg/TTP-Flag using 
Lipofectamine Plus (Invitrogen) according to the 
vendor’s protocol. Stably transfected cells were selected 
in normal growth medium containing 100 µg/ml G418, 
200 µg/ml hygromycin B (Invitrogen), and 2 µg/ml 
doxycycline (Dox) (Clontech) for 2-3 weeks. Individual 
clones were isolated by limiting dilution in 96-well 
plates. Positive HeLa-Tet-Off/TTP-Flag clones were 
screened by growing cells in the presence or absence of 
Dox (2 μg/ml) to induce expression of TTP-Flag, 
respectively; the absence of Dox allows for TTP-Flag 
expression. For stable cell maintenance the hygromycin 
B concentration was reduced to 100 µg/ml. Unless 
otherwise indicated, HeLa Tet-Off/TTP-Flag cells were 
grown in the absence of Dox for 48 hr to induce TTP-
Flag expression.  
 
HeLa Tet-Off/TTP-Flag cells were transiently 
transfected with p53-responsive promoter luciferase 
reporter vector pp53-Luc or control vector pTA-Luc 
(Clontech) along with control pRL-TK renilla vector 
(Promega) using Lipofectamine Plus. The E6-AP 
coding region or 3’UTR were PCR amplified from 
HeLa cDNA as described [66]. E6-AP coding region 
was cloned into the expression vector pcDNA3.1/Zeo 
(Invitrogen) to generate pcDNA3.1/E6-APΔ3'UTR. 
Luciferase reporter construct containing the E6-AP 
3’UTR was prepared by cloning E6-AP 3’UTR into 
pcDNA3.1/Zeo containing the luciferase cDNA [66]. 
Cells were transfected in DMEM for 3 hr after which 
cells were grown in complete medium in the presence 
or absence of 2 µg/ml Dox for 48 hr. Transfected cells 
were lysed in reporter lysis buffer (Promega) and 
assayed for luciferase and renilla activities using the 
Dual-Luciferase Assay System (Promega). Luciferase 
reporter gene activities were normalized to renilla 
activity and all results represent the average of triplicate 
experiments. 
 
TTP-Flag expressing adenovirus was created by cloning 
TTP-Flag cDNA into the shuttle vector Dual-CCM-
CMV-EGFP (Vector Biolabs) that contains dual CMV 
promoters to drive expression of TTP-Flag and GFP. 
Construction of TTP-expressing adenoviral vector 
(AdGFP/TTP) and production of viral stocks were 
conducted by Vector Biolabs. Control GFP-expressing 
adenovirus (AdGFP) was purchased from Vector 
Biolabs. HeLa, SiHa and CaSki cells were infected with 
AdGFP or AdGFP/TTP using a MOI of 100 in serum-
free DMEM for 2 hr after which FBS was added to a 
final concentration of 10%. 48 hr after infection, cells 
were harvested in SDS-PAGE lysis buffer for western 
blot analysis. 
 
Immunoblot analysis. Cells were lysed in SDS-PAGE 
lysis buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 
2% SDS, 0.1% bromophenol blue, 10% glycerol) and 
protein content was determined using a BCA protein 
assay with BSA as standard (Pierce Biotechnology). 
Where indicated, nuclear lysates were prepared by 
resuspending cells in lysis buffer (10 mM HEPES pH 
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DTT, 0.5% NP-40) containing 0.5 mM PMSF and 
protease inhibitor cocktail (Sigma) and incubated on ice 
for 10 min. Cells were centrifuged at 13000 rpm for 10 
min and the nuclear pellet was washed 3 times with 
lysis buffer. Nuclei were lysed in RIPA buffer (50 mM 
Tris-Cl pH 8.0, 156 mM NaCl, 4 mM EDTA, 1% SDS, 
1 % Triton X-100, 1% Na-deoxycholate). Lysates (50 
µg) were separated by 10% SDS-PAGE, transferred to 
PVDF membranes (Bio-Rad), and probed with 
antibodies against Flag epitope (M2; Sigma), TTP (Ab-
36558, Abcam), p53 (DO-1, Calbiochem), hTERT (Ab-
1, Calbiochem), and E6-AP (BD Biosciences) at 
dilutions specified by the vendor. Blots were stripped 
and then probed with antibodies against β-actin (Clone 
C4, MP Biomedicals) or nucleoporin (BD Biosciences). 
Detection and quantitation of blots were performed as 
described [66].  
 
mRNA analysis.  Total RNA was extracted from cells 
using Trizol reagent (Invitrogen). Northern blotting was 
performed as previously described [67] and probed with 
P
32-labeled DNA probes synthesized for TTP, E6-AP 
and actin (Promega). cDNA synthesis and RT-PCR 
analysis of mRNA was accomplished as described [66]. 
The sequences for PCR primers used were: TTP sense, 
5’-TCCACAACCCTAGCGAAGAC-3’ and TTP anti-
sense, 5’-GAGAAGGCAGAGGGTGACAG-3’; p53 
sense, 5’-CAGCCAAGTCTGTGACTTGCACGTAC-
3’ and p53 antisense, 5’-CTATGTCGAAAAGTGTTT 
CTGTCATC-3’; hTERT sense, 5’-GTGACCGTGGTT 
TCTGTGTG-3’ and hTERT antisense, 5’-TCGCCTGA 
GGAGTAGAGGAA-3’; HPV18 E6 sense, 5’-CGCGC 
TTTGAGGATCCAA-3’ and HPV18 E6 antisense, 5’-
TATGGCATGCAGCATGCG-3’; HPV18 E7 sense, 5’-
TATGCATGGACCTAAGGCAAC-3’ and HPV18 E7 
antisense, 5’-TTACTGCTGGGATGCACACC-3’; E6-
AP sense, 5’-GCTTGAGGTTGAGCCTTTTG-3’ and 
E6-AP antisense, 5’-CCAATTTCTCCCTTCCTTCC-
3’; GAPDH sense, 5’-CCACCCATGGCAAATTCCAT 
GGCA-3’ and GAPDH antisense, 5’-TCTAGACGGCA 
GGTCAGGTCCACC-3’. Real-time PCR (qPCR) was 
performed using the 7300 Real-Time PCR Assay 
System (Applied Biosystems) with SYBR green PCR 
master mix (Applied Biosystems) and primers for E6-
AP and GAPDH according to the vendor's protocol.  
 
Cell growth and senescence. Cell growth was assayed 
using the MTT-based cell growth determination kit 
(Sigma) as previously described [68]. For cellular 
senescence studies, 1 x 10
4 HeLa Tet-Off/TTP-Flag 
cells were grown in 35mm diameter dishes in the 
presence or absence of 2 µg/ml Dox. Twelve days later, 
the cells were stained at pH 6.0 with X-Gal (5-bromo-4-
chloro-3-indolyl-ß-D-galactopyranoside; Cell Signaling 
Technology) to visualize senescence associated-β-
galactosidase (SA-β-gal) activity.  
 
Fluorescence microscopy. HeLa Tet-Off/TTP-Flag cells 
were plated on coverslips in a 24-well plate and grown 
in the presence or absence of 2 µg/ml Dox. After 48 hrs, 
the cells were fixed in 4% paraformaldehyde for 10 min 
and permeabilized with 0.1% Triton X-100 in PBS for 5 
min. The cells were blocked with 10% normal goat 
serum and 3% BSA diluted in PBST (PBS + 0.1% 
Tween-20) for 1 hr. Cells were incubated for 1 hr at RT 
with anti-p53 antibody (DO-1, Calbiochem; 1:100) 
diluted in blocking buffer. After washing, the cells were 
incubated with fluorescein-conjugated goat anti-mouse 
secondary antibody (MP Biomedicals; 1:150) for 1 hr at 
RT. DAPI (Invitrogen) was used for nuclear counter-
staining. Coverslips were mounted on glass slides and 
visualized using an Axiovert 200 inverted microscope 
(Zeiss). Cell morphology was examined by staining 
fixed and permeabilized cells with DAPI and rhodamine 
phalloidin (Invitrogen) according to the vendor's 
instructions. 
 
Telomerase activity.  Telomerase activity was 
determined in HeLa Tet-Off/TTP-Flag lysates 48 hr 
after TTP induction using the PCR-based TRAP assay 
as previously described [69]. PCR products were 
resolved on a 10% non-denaturing polyacrylamide gel 
and visualized by silver staining [70]. 
 
Immunoprecipitations. HeLa Tet-Off/TTP-Flag (1.25 x 
10
5 cells) were grown in 100 mm diameter dishes in the 
presence or absence of 2 µg/ml Dox for 48 hr. Cells 
were lysed in polysome lysis buffer (100 mM KCl, 
5mM MgCl2, 10mM HEPES pH 7.0, 0.5% NP-40, and 
1 mM DTT) containing 100 U/ml RNase inhibitor 
(Ambion) and protease inhibitor cocktail (Sigma). 
Cytoplasmic extracts were separated from nuclei by 
centrifugation at 20,000g for 30 min. 700 µl of IP buffer 
(50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 
0.05% NP-40) was added to 500 µg of lysate and 
immunoprecipitation of TTP-bound RNA was 
accomplished by incubating lysates with equal amounts 
(30 µg) of anti-Flag mAb or mouse IgG pre-coated to 
protein A/G PLUS agarose (Santa Cruz Biotechnology) 
overnight at 4°C. Immunoprecipitates were collected by 
brief centrifugation and washed 4 times with IP buffer. 
Total RNA was isolated using 1 ml Trizol per IP 
reaction and then used for cDNA synthesis [66]. Real-
time PCR reactions were performed using 1 µl of cDNA. 
Data was plotted as 1/Ct to represent the abundance of 
E6-AP or GAPDH mRNA in each IP sample. 
 
Immunohistochemical analysis.  Immunohistochemical 
analysis of TTP expression was performed using 
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contained 12 cases of normal and inflammatory tissues 
of cervix and 36 cases of cervical cancer graded by 
histology. TTP immunostaining was performed using 
TTP polyclonal antibody (Ab-36558, Abcam) at 8 
μg/ml (1:400). Standard staining protocol was 
performed and stained tissue sections were evaluated 
for intensity of staining as described [44] using two 
blinded investigators (S.S and V.K.). For each tissue 
section, the percentage of positive cells was scored on a 
scale of 0 to 4 : 0 (0% positive cells), 1 (< 25%), 2 (25-
50%), 3 (50-75%) or 4 (> 75%). Staining intensity was 
scored on a scale of 0 to 3; 0-negative, 1-weak, 2-
moderate, or 3-strong. The two scores were multiplied 
to give an immunoreactivity score (IRS) ranging from 0 
to 12, with scores in the range of 0-6 grouped in the 
category of Low IRS and those in the range of 7-12 
representing High IRS.  
 
Statistical analysis. The data are expressed as the mean 
+/- SD. Student's t-test was used to determine 
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